BERKELEY HEIGHTS, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Genta Incorporated announced today that senior management will update the Company’s corporate, clinical, and regulatory activities at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Monday, November 7, 2005 at 8:00 a.m. ET. Genta’s presentation will be webcast live and can be accessed through the investor relations section of the Company’s website, http://www.genta.com, where the slide presentation will be archived. The conference will be held at the New York Palace Hotel in New York, NY.
About Genta
Genta Incorporated is a pharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company’s research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA-based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection, the Company’s lead compound from its oligonucleotide program, is currently undergoing late-stage, Phase 3 clinical testing. In 2005, the Company initiated a “rolling” New Drug Application to the Food and Drug Administration for the use of Genasense plus fludarabine and cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. The Company has also indicated its intention to submit in 2005 a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for the use of Genasense plus dacarbazine in patients with advanced melanoma. The leading drug in Genta’s small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company’s Annual Report/Form 10-K for 2004.
Genta Incorporated
CONTACT: Investor Relations, of TS Communications Group, LLC,+1-908-286-3980, info@genta.com; or Greg Tiberend, Media Relations, ofRichard Lewis Communications, +1-212-827-0020
Web site: http://www.genta.com/
